Alprostadil - PowderJect

Drug Profile

Alprostadil - PowderJect

Alternative Names: Prostaglandin E1 - PowderJect

Latest Information Update: 13 Dec 2000

Price : $50

At a glance

  • Originator PowderJect Pharmaceuticals; PowderJect Therapeutics
  • Developer Evotec AG; PowderJect Pharmaceuticals; PowderJect Therapeutics
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 13 Dec 2000 Discontinued-II for Erectile dysfunction in United Kingdom (Injection)
  • 10 Feb 2000 PowderJect has completed a phase II trial of alprostadil in patients with erectile dysfunction
  • 20 Jul 1999 Two clinical studies have been added to the adverse events and pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top